Shares of top-rated medical firms Regeneron Pharmaceuticals and Abiomed hit new highs in the stock market early Tuesday after both companies beat quarterly earnings estimates and raised guidance. Regeneron (REGN) reported Q2 earnings of $2.89 a share excluding one-time items, up 17% from a year earlier and 12 cents above analysts’ consensus, according to Thomson Reuters. Revenue jumped 50% to $999 million, $11 million more than
We’re in the middle of another big week for earnings, with a slew of medical-related companies among those reporting. Regeneron (REGN) hit a new high in the stock market today after issuing better-than-expected Q2 earnings. The biotech also raised its growth forecast for its blockbuster Eylea drug. Shares gapped up 6% in big volume, hitting a fresh high and clearing the 600 price level for the first time intraday. Regeneron is now extended from a
Top-rated medical stocks Regeneron Pharmaceuticals (REGN) and Abiomed (ABMD) both hit new highs on the stock market early Tuesday after both companies beat quarterly earnings estimates and raised guidance. Regeneron reported Q2 earnings of $2.89 a share excluding one-time items, up 17% from the year-earlier quarter and 12 cents above analysts’ consensus, according to Thomson Reuters. Revenue jumped 50% to $999 million, $11 million above consensus.